News for Seer, Inc. (SEER)

[url="]BeOne Medicines Ltd.[/url] (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast canc

Seer (SEER) has initiated an ambitious study focused on discovering new blood-based biomarkers for cancer diagnostics in young adults, specifically targeting th

Seer, Inc. (SEER) and Korea University initiate a groundbreaking 20,000-sample proteomics study. The study aims to develop AI-driven diagnostics for early c

First-of-its-kind study will use Seer's next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based prot

GE HealthCare (Nasdaq: GEHC) today announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)for clinicians now recommend considering

**media[640917]**

Seer (SEER) has introduced its latest Proteograph Product Suite, including the Proteograph ONE Assay and the SP200 Automation Instrument. This innovative soluti

Seer (SEER) launches its new Proteograph® Product Suite to revolutionize deep proteomic studies. The suite doubles throughput to over 1,000 samples wee

Market Analysis by covering: McDonald’s Corporation, Amazon.com Inc, US Dollar Index Futures. Read 's Market Analysis on Investing.com

Revenue: $4.2 million for Q1 2025, a 37% increase from $3.1 million in Q1 2024.Product Revenue: $2.9 million, including $5,000 from related parties.Service Rev

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the presentation o

PR NewswirePRINCETON, N.J., April 14, 2025 Interim Results from FDA-Funded Study Reinforces HyBryte'sâ„¢ Rapid Response and Strong Safety ProfilePRINCETON,

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the publication of a comprehensive review in

**media[583212]**

**media[579906]**

The heavy selling pressure might have exhausted for Seer (SEER) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

**media[575885]**

Seer (SEER) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

”” First and only EZH2 inhibitor approved by the NMPA ”” ”” HUTCHMED's fourth product, and its first approval in hematological malignancies ”” HONG KO